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Abstract
Objective To assess the effect of second generation, home based
telehealth on health related quality of life, anxiety, and depressive
symptoms over 12 months in patients with long term conditions.
Design A study of patient reported outcomes (the Whole Systems
Demonstrator telehealth questionnaire study; baseline n=1573) was
nested in a pragmatic, cluster randomised trial of telehealth (the Whole
Systems Demonstrator telehealth trial, n=3230). General practice was
the unit of randomisation, and telehealth was compared with usual care.
Data were collected at baseline, four months (short term), and 12months
(long term). Primary intention to treat analyses tested treatment
effectiveness; multilevel models controlled for clustering by general
practice and a range of covariates. Analyses were conducted for 759
participants who completed questionnaire measures at all three time
points (complete case cohort) and 1201 who completed the baseline
assessment plus at least one other assessment (available case cohort).
Secondary per protocol analyses tested treatment efficacy and included
633 and 1108 participants in the complete case and available case
cohorts, respectively.
Correspondence to: S P Newman stanton.newman.1@city.ac.uk
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Setting Provision of primary and secondary care via general practices,
specialist nurses, and hospital clinics in three diverse regions of England
(Cornwall, Kent, and Newham), with established integrated health and
social care systems.
Participants Patients with chronic obstructive pulmonary disease
(COPD), diabetes, or heart failure recruited between May 2008 and
December 2009.
Main outcome measures Generic, health related quality of life
(assessed by physical andmental health component scores of the SF-12,
and the EQ-5D), anxiety (assessed by the six item Brief State-Trait
Anxiety Inventory), and depressive symptoms (assessed by the 10 item
Centre for Epidemiological Studies Depression Scale).
Results In the intention to treat analyses, differences between treatment
groups were small and non-significant for all outcomes in the complete
case (0.480≤P≤0.904) or available case (0.181≤P≤0.905) cohorts. The
magnitude of differences between trial arms did not reach the trial
defined, minimal clinically important difference (0.3 standardised mean
difference) for any outcome in either cohort at four or 12 months. Per
protocol analyses replicated the primary analyses; the main effect of
trial arm (telehealth v usual care) was non-significant for any outcome
(complete case cohort 0.273≤P≤0.761; available case cohort
0.145≤P≤0.696).
ConclusionsSecond generation, home based telehealth as implemented
in the Whole Systems Demonstrator Evaluation was not effective or
efficacious compared with usual care only. Telehealth did not improve
quality of life or psychological outcomes for patients with chronic
obstructive pulmonary disease, diabetes, or heart failure over 12 months.
The findings suggest that concerns about potentially deleterious effect
of telehealth are unfounded for most patients.
Trial Registration ISRCTN43002091.
Introduction
Over the coming decades, extended life expectancy and low
fertility will result in a shift in the old age dependency ratio in
many countries including the United Kingdom, with a greater
proportion of the population at retirement age than at working
age.1-3 Despite some positive changes in levels of old age
disability4 and years of self reported good health,5 greater
numbers of older people living with long term conditions are
likely to present major challenges for health and social care
systems in the years ahead.2 3 6 7
One response to these pressures from health systems has been
the introduction of localised telehealth services. Telehealth
enables the remote exchange of data between a patient and
healthcare professionals to facilitate diagnosis, monitoring, and
management of long term conditions.8 9 Some telehealth systems
incorporate an educational component aimed at improving
patient knowledge10 and self care (for example, treatment
adherence).11 12 Telehealth systems that send physiological or
symptom data to a remote monitoring centre can alert healthcare
professionals when disease specific clinical parameters are
breached. Thus, telehealth affords the opportunity for earlier
intervention, which may reduce the frequency with which
expensive hospital based care is required.
Evaluations of service innovations such as telehealth need to
assess the effect from the patient’s perspective, using self report
measures such as quality of life (QoL), psychological outcomes,
and acceptability of services. This approach is in line with the
developing agenda on patient reported outcomes,13-17 and
complements more familiar outcomes such as service use, costs,
and mortality.
Generic health related QoL, anxiety, and depression are
outcomes relevant to patients with the three long term conditions
that are the focus of the Whole Systems Demonstrator (WSD)
Evaluation.18 It is well established that health related QoL is
reduced and anxiety and depression are elevated for patients
with diabetes,19-21 chronic obstructive pulmonary disease,22-24
and heart failure.25-27Health related QoL, anxiety, and depression
have been linked with poorer outcomes on endpoints including
self management, disease control, health service use, costs, and
mortality.28-32
However, evidence for the effect of telehealth on these outcomes
is unclear. At least seven systematic reviews have examined
this effect on health related QoL in heart failure,33-39 and while
most conclude that telehealth is beneficial, such inferences are
not supported by the evidence they present. Typically, the
reviews are poorly reported (for example, they report howmany
studies found a significant association but not howmany studies
looked for an association and failed to find one35), combine
outcomes comprising measures that are conceptually distinct
(for example, health related QoL combined with patient
satisfaction and treatment adherence37), and fail to balance the
evidence appropriately.39
In the two most transparent reviews, only one of three34 and
three of seven36 studies that evaluated the monitoring of
telehealth based vital signs reported any significant associations
between telehealth and improvements in health related QoL. In
a recent randomised controlled trial of third generation
telehealth40 that is not included in the cited reviews, researchers
found no effect of telehealth on depression scores over 24
months, but found an overall benefit on one of eight SF-36
subscales.41 Overall, claims that telehealth improves health
related QoL for patients with heart failure are unsubstantiated.38
Two systematic reviews have examined the effect of telehealth
on health related QoL for patients with chronic obstructive
pulmonary disease. They showed ambivalent evidence; half the
studies suggested a significant positive effect on health related
QoL, and the other half showed no effect.42 43
One systematic review has investigated the effect of telehealth
on health related QoL in diabetes.44 This review confounds two
patient reported outcomeswith different meanings: health related
QoL and patient satisfaction. Of only five studies that actually
measured health related QoL, three found no difference between
telephone support and usual care,45-47 one failed to report
differences between telehealth and usual care48 and one pre-post
study of telehealth found significant improvements on only
three of eight SF-36 subscales (role-physical, bodily pain, and
social functioning).49
Despite their relevance, few studies have examined anxiety or
depression. This omission is important, given concerns about
the potential detrimental effects of telehealth on patients. Such
concerns include the greater burden of work on patients50 and
increased sense of isolation for vulnerable people by reducing
face-to-face contact with healthcare professionals.8
Notwithstanding steady growth in telehealth studies over the
past 20 years, robust evidence to inform policy decisions is
lacking.51 Systematic reviews show that although enthusiasts
have written much about the promise of telehealth, most studies
do not meet orthodox quality standards.42 52 53 Furthermore,
evidence from a few small trials of variable methodological
quality is difficult to interpret.54
There is a danger of relying on even high quality systematic
reviews if they pool data from low quality studies. This risk
was underscored in a large scale, multicentre evaluation of
automated telephone based monitoring for patients with heart
failure.55By contrast with a recently updated Cochrane review,36
this study found no evidence of benefit for interactive
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telemonitoring on any outcome examined. These results
highlight the need for rigorous, large scale, high quality
independent studies to evaluate healthcare interventions before
wide scale adoption.54 55
WSD evaluation
Part of the UK government’s response to this need for robust
evidence was to fund the WSD Evaluation18 to investigate the
effects of two broad classes of technologies (telehealth and
telecare) on a comprehensive range of outcomes in regions of
England that had undergone theWhole Systems Redesign (web
appendix 1). The design, protocol, and objectives of the WSD
Evaluation have been reported in detail elsewhere.18Briefly, the
evaluation comprises a pragmatic, cluster randomised controlled
trial of telehealth for service users with long term conditions
(chronic obstructive pulmonary disease, diabetes, heart failure;
known as the WSD telehealth trial) and an equivalent trial of
telecare for service users with social care needs (the WSD
telecare trial).
These cluster randomised controlled trials evaluate a
comprehensive range of healthcare utilisation outcomes and
mortality. The evaluation was designed to avoid some of the
shortcomings of previous research by conducting large,
methodologically rigorous, multicentre trials across three regions
of England. Each trial included a nested questionnaire study
(the WSD telehealth questionnaire study and WSD telecare
questionnaire study) to assess outcomes reported by patients
and carers (for example, health related QoL, anxiety, depressive
symptoms, functional ability, self care behaviour), and cost
effectiveness based on quality adjusted life years.
Additional qualitative studies of purposive subsamples explored
the experiences of patients, carers, healthcare professionals, and
healthcare organisations. Collectively, the WSD Evaluation is
the largest and most comprehensive investigation of telehealth
and telecare so far. In the present study, we focus on the WSD
telehealth questionnaire study and report on the effect of
telehealth on health related QoL and two psychological
outcomes (anxiety and depressive symptoms). For this part of
the WSD Evaluation, we assessed the hypothesis that
introduction of a broad class of home based telehealth improves
quality of life, anxiety, and depressive symptoms over a 12
month period for patients with chronic obstructive pulmonary
disease, diabetes, or heart failure, compared with usual care
only.
Methods
Design and setting
The WSD telehealth trial is a pragmatic, cluster randomised
controlled trial of telehealth (n=3230). This paper reports on
the nested WSD telehealth questionnaire study, which was
designed to include 1650 participants. Between May 2008 to
December 2009, we recruited participants for the WSD
telehealth trial, across three sociodemographically distinct
regions in England (rural Cornwall, rural and urban Kent, and
urban Newham in London) comprising four primary care trusts.
Participants were also invited to take part in theWSD telehealth
questionnaire study, a supplementary investigation of patient
reported outcomes. We assessed participants at four and 12
months after recruitment (the last 12month assessment occurred
in December 2010). Figure 1⇓ shows a CONSORT diagram of
general practice and participant flow into the parent trial and
the questionnaire study (n=1573). Table 1⇓ compares sample
characteristics at baseline across the parent trial and the nested
questionnaire study.
Cluster level recruitment and randomisation
Allocation was conducted at the cluster (general practice) level.
All 365 general practices in the four primary care trusts were
invited to participate. To maximise participation, the evaluation
adopted a pragmatic approach: each practice provided
intervention participants for one technology (telehealth or
telecare) in one trial and control participants for the other
technology (telecare or telehealth) in the other trial, ensuring
equity of access to advanced assistive technology at the level
of the practice population.18Consenting practices were allocated
to the intervention and control groups by the trial statistician
(HD), using a centrally administered minimisation algorithm
that ensured comparability across trial arms in terms of practice
size; deprivation; proportion of patients from non-white ethnic
groups; prevalence of diabetes, chronic obstructive pulmonary
disease, and heart failure; and WSD site.
There was no blinding for practices, participants, or assessors,
although most measures in the WSD telehealth and telecare
questionnaires studies were self reported. Participants allocated
to the control arm were informed that they would be offered the
appropriate technology at the end of the 12 month trial period,
subject to a further needs assessment.
Participant level recruitment
In participating practices, patients with chronic obstructive
pulmonary disease, diabetes, or heart failure were deemed
eligible on the basis of one of the following:
• Inclusion on the relevant Quality Outcomes Framework
register in primary care
• A confirmed medical diagnosis in primary or secondary
care medical records, as indicated by general practice Read
codes or ICD-10 (international classification of diseases,
10th revision) codes
• Confirmation of disease status by a local clinician (such
as general practitioner or community matron) or hospital
consultant.
Patients were not excluded on the basis of additional physical
comorbidities. However, participants were required to have a
telephone landline for broadband internet connection (at all
WSD sites), and a digital television (in Newham). Other
financial costs (including phone calls and data transmission to
the monitoring centres) were paid for by the local WSD project
teams. Since the telehealth system used in the trial required
participants to read and respond to textual information presented
via a base unit or television screen, sufficient English language
literacy was required, as determined by the local WSD project
team. Cognitive impairment was not an exclusion criterion for
the WSD telehealth trial, provided that an informal carer was
available to assist with use of the telehealth system. However,
cognitive impairment was an exclusion criterion for the
questionnaire study because we aimed to collect self reported
data without third party influence. Participants with physical
impairments could receive practical assistance with completing
the questionnaire battery from an independent trained researcher.
All 15 171 potentially eligible patients in participating practices
were contacted about the study. To meet ethical obligations,
these patients were initially sent and asked to complete a data
sharing consent form if they were interested in the study and
willing to allow their medical and social care data to be shared
with the WSD research team. Follow-up letters and telephone
calls encouraged responses.
Once data sharing consent was received eligibility was
confirmed by the local WSD project team and eligible patients
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were contacted to arrange a home visit to discuss the research
in more detail. At this visit, the suitability of the participant’s
home infrastructure was checked, and a participant information
sheet and consent form were provided. Participants provided
written consent and indicated whether they would be willing to
take part in the supplementary questionnaire study. Those
willing were contacted by trained interviewers to arrange a
baseline interview in the participant’s home. At baseline
interview, patients received a second information sheet relating
specifically to the questionnaire study, and signed a second
consent form for this part of the evaluation.
To minimise participant burden and create mutually exclusive
subgroups for subsequent disease specific analyses (not reported
here), participants with at least two of the three long term
conditions were allocated to a single index condition using
simple randomisation. Based on a prospective power calculation
(see below), we aimed to recruit 1650 participants into the
questionnaire study with an approximately even split between
the three long term conditions (fig 2⇓). Recruitment ended in
December 2009.
Telehealth treatment (intervention arm)
To facilitate comparisons between clinical studies, four classes
(or “generations”) of telehealth have recently been proposed on
the basis of the type of data transfer, decision making ability of
the care provider reviewing the data, and level of integration of
all systems with the patient’s primary care structure.40
First generation telehealth comprises non-reactive data collection
and analysis systems. Measurements of interest are collected
and transferred to the care provider asynchronously (that is, by
store and forward protocols). There is no full telemedical system,
and the provider cannot respond immediately to patient data.
Second generation systems have a non-immediate analytical or
decision making structure. Data transfer is synchronous—that
is, there is some real time processing of patient data using, for
example, automated algorithms to interpret the data. Care
providers can recognise important changes in essential
measurements, but delays can occur if the systems are only
active during office hours.
Third generation systems provide constant analytical and
decision making support. Monitoring centres are physician led,
staffed by specialist nurses, and have full therapeutic authority
24 h per day, seven days per week. Fourth generation systems
are an extension of third generation systems, comprising
invasive (such as with surgical implantation) and non-invasive
telemedical devices for data collection. The complexity of
incoming information and subsequent therapeutic decisions
requires the continuous presence of a physician.
WSD sites delivered variations of telehealth, but all systems
focused on monitoring vital signs, symptoms, and self
management behaviour. They provided general and disease
specific health education, with non-immediate review by
specialist nurses and other care providers. This configuration
most closely approximates second generation telehealth.
Web appendix 2 and figure 3⇓ describe the WSD telehealth
intervention. Web figure 1 shows the provision of peripheral
telehealth devices to intervention participants according to
diagnosis of long term condition in eachWSD site. Sites differed
in the number of peripheral devices installed per participant,
with a mode (across all long term conditions) of two in Cornwall
and three in Kent and Newham. Web figure 2 shows the early
removal of telehealth from participants for reasons other than
death, by site. Differences in functionality of the telehealth
equipment supplied, type and number of peripheral devices
provided, transfer of data to the monitoring centres, triage or
risk stratification, and response pathways reflected variations
that would occur if telehealth was implemented across the UK’s
entire health system.
Usual care treatment (control arm)
Participants allocated to the control arm continued to receive
their existing healthcare and social services, in line with local
protocols, for the 12 months of the trial. Across the three WSD
sites, healthcare was provided by a combination of community
matrons, district nurses, specialist nurses, general practitioners,
and hospital services based on clinical need. Patients had
pre-established, tailored care plans that included routine
assessments at a frequency appropriate for their disease
severity—typically ranging from once per week to once or twice
per year. Control participants had no telehealth or telecare
equipment installed their homes for the duration of the study.
A Lifeline pendant (a personal alarm) plus a smoke alarm linked
to a monitoring centre were not, on their own, sufficient to
classify as telecare for current purposes. We planned to reassess
control participants at the end of the trial and, if still eligible,
offer them telehealth.
All participants (intervention and control) were beneficiaries of
theWhole Systems Redesign, which was a precondition of sites’
participation in the trial. Putative benefits for patients included
a better understanding of their condition and how to look after
themselves through the development of self care behaviours
and the continued support of services such as community
matrons (web appendix 1).
Trial assessment procedures
Outcomes were assessed at the level of the patient. At baseline,
questions on outcome measures were answered by participants
with a trained researcher on hand to explain or clarify the
meaning of particular questions or assist with completing the
questionnaire if participants were physically unable to do so.
After the baseline interview, two further assessments were
conducted. A short term assessment was conducted at about
four months (median duration 127 days (interquartile range 37);
132 days (40) for control group, 126 days (35) for intervention
group), and a long term assessment at around 12 months (347
days (49); 358 days (48), 342 days (47)). Duration at both
assessments was similar across trial arms.
The questionnaire battery was the same at baseline and at short
term; long term assessment included two additional scales
measuring functional status56 and impact of illness57 (not reported
here). At short term assessment, the survey battery was primarily
administered as a postal survey with one reminder letter for
non-responders; some participants also received telephone
reminders. At long term assessment, the survey was posted to
participants and non-responders were contacted to arrange a
home interview with a trained researcher, in line with the
baseline protocol. Participants who did not complete a
questionnaire at short term were still invited to complete a
questionnaire at long term. However, participants whowithdrew
from the trial, including intervention participants who asked for
the telehealth equipment to be removed before the end of the
12 month trial period, were not sent further questionnaires after
their withdrawal date.
Patient reported outcomes
Findings in the current report are based on instruments assessing
different domains of generic health related QoL (SF-12, EQ-5D),
anxiety (Brief State-Trait Anxiety Inventory (STAI)), and
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depressive symptoms (Center for Epidemiologic Studies
Depression Scale (CESD-10)).
The SF-1258 is a 12 item measure of general health status and
health related QoL that uses norm based scoring for the general
population in the United States in 1998. The instrument was
scored in two subscales, the physical component summary score
and the mental component summary score; higher scores
represent better health related QoL. The SF-12 has shown good
test-retest reliability, validity, and responsiveness, and is
recommended for patients with heart failure.59
The EQ-5D60 assesses five domains of generic health related
QoL (mobility, self care, usual activities, pain and discomfort,
anxiety and depression) and can generate either a health state
(of 243 different states) or a single summary score (higher scores
reflect better health related QoL). The EQ-5D has shown good
validity and responsiveness and has been recommended for
patients with diabetes61 and, more cautiously, for patients with
chronic obstructive pulmonary disease62 and heart failure.59 For
current purposes, the summary score was used.
The Brief STAI63 is a six item measure of state anxiety that has
shown acceptable reliability and validity.63 64 It is widely used
in clinical research, notably in studies of patients with diabetes.65
The state version, rather than the trait version, of the Brief STAI
was used (higher scores reflect greater state anxiety).
The CESD-1066 is a 10 item measure of depressive symptoms
covering cognitive, emotional, and behavioural domains. It has
acceptable validity and reliability,66 and sensitivity and
specificity.67 The original 20 item version has been used widely
with clinical populations, including chronic obstructive
pulmonary disease68 and heart failure,69 although both versions
of the scale include items that confound symptoms of physical
illness with symptoms of depression (for example, “I felt that
everything I did was an effort”; “My sleep was restless”).70
Scores range from 0 to 30, with higher scores indicating more
depressive symptoms.
Minimal clinically important differences (MCIDs) have not
been established for these patient reported outcomes. To evaluate
the magnitude of any treatment effect, we regarded a trial
defined MCID as an effect size equivalent to Cohen’s d=0.3.
This magnitude represents a “small” effect in the behavioural
sciences.71
Covariates in the analyses
Data were collected on a range of sociodemographic and trial
related characteristics that could plausibly be related to the study
outcomes. These variables were used as covariates in the main
analyses. Date of birth and sex were extracted from general
practice records. Ethnicity was assessed by self report, using
16 response categories based on standard UK categories from
the Office of National Statistics72; missing responses were
subsequently completed using data frommedical records, where
available. Education was assessed by self report using five
response categories ranging from no formal education to
graduate or professional level. We used participants’ postcodes
to allocate an index of multiple deprivation score.73
Comorbidity was assessed by a count of diagnosed conditions
in hospital episode statistics over the three years before the trial
began. The WSD project teams provided data for participants’
WSD site; the presence or absence of a diagnosis of chronic
obstructive pulmonary disease, diabetes, and heart failure; and
the number and type of telehealth peripheral devices installed.
TheWSD evaluation team held data for participants’ allocation
(to telehealth or usual care) and calculated the duration of
exposure to telehealth (in days) at the time each assessment
questionnaire was completed. Owing to the variability in
telehealth duration for intervention participants at short term
and long term assessments, this variable was included as a
covariate.
Sample size
For the telehealth questionnaire study, a power calculation was
conducted on the basis of detecting a small effect size (Cohen’s
d=0.3), allowing for an intracluster correlation coefficient of
0.05, power of 80%, and P<0.05. This calculation indicated that
about 500 patients would be required to allow sufficient power
to detect this small difference, ranging from 420 participants
(five from each of 84 practices) to 520 participants (10 from
each of 52 practices). These numbers were inflated by 10% to
allow for the maximum possible increase in sample size due to
variable cluster size.74 The required sample size thus increased
to 550. For sufficient power in our secondary subgroup analyses
(not reported here), we aimed to recruit 550 patients per long
term condition, or 1650 overall. All analyses reported here
exceed the required sample size (550) and are therefore
adequately powered.
Statistical methods
Missing self reported data could occur at the questionnaire level
or at the item or scale level. A participant who completes the
questionnaire battery at baseline could fail to complete the
questionnaire at short term or long term. Alternatively, a
participant who largely completes a questionnaire could
nevertheless fail to provide responses to certain items or may
miss out whole scales within the battery.
For the outcomes reported, missing values at the questionnaire
level were not imputed. We imputed missing values at the item
or scale level using two methods. If a missing value belonged
to a scale and at least 50% of responses were available for the
scale (for a particular participant), we used the series mean for
that scale (for that participant) to fill in missing values. If a
missing value for an item did not belong to a scale (for example,
index of multiple deprivation score) or if fewer than 50% of
scale items were completed, missing values (either for items or
scale totals) were multiply imputed (m=10), on the basis of
available data from several scales and items across all
participants.We didmultiple imputation using theMarkov chain
Monte Carlo function (SPSS).
We repeated analyses on each of the ten imputed datasets, and
thereafter used standard multiple imputation procedures to
combine the multiple scalar and multivariate estimates75-77 with
SPSS (version 19) and NORM.78 We explored the influence of
missing data at the questionnaire level by conducting complete
case analyses (participants with data for all variables at all time
points) and available case analyses (participants with data for
all variables at baseline and at least one other time point).
Depending on the reasons for missingness, both these
approaches can generate biased results, but they are used here
as sensitivity analyses to assess the robustness of the findings.
General practices were the unit of randomisation and were
directly involved in the delivery of care to all participants, which
could result in participants within practices being more similar
than participants between practices. Causes of similarity within
practices include pre-existing case mix differences between
practice populations, and both general and specific practice
effects (for example, factors that facilitate or inhibit access,
general practitioner case load, the extent to which care is centred
around the patient). To account for practice differences,
multilevel modelling was used with observations (at different
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;346:f653 doi: 10.1136/bmj.f653 (Published 26 February 2013) Page 5 of 20
RESEARCH
time points) nested within participants, and participants nested
within practices. The model included random intercepts and
random slopes at the practice level.
Repeated measures for each outcome over the trial period were
analysed with the linear mixed model procedures in SPSS. We
used restricted maximum likelihood to estimate model
parameters, with an ante-dependent (first order)
variance-covariance matrix structure. A separate analysis was
conducted for each of the five outcome variables, and the main
effect of trial arm (telehealth v usual care) was estimated to
answer the principal research question. We estimated the main
effect of time to determine whether the outcomemeasures were
different in the short and long term. The interaction between
trial arm and time (trial arm×time) was also estimated to
determine whether the trial arm had differential effects at short
term and long term.
In each model, the baseline measure of a respective outcome
variable was treated as a covariate, with the measures at short
term and long term treated as the outcome. Covariates included
in the model adjusted for baseline distributional differences
between trial arms on sociodemographic and trial related
variables that could be related to the outcomes.
Sociodemographic covariates included age, sex, ethnicity (white
or non-white); education (ordinal, five levels); deprivation
(continuous data); diagnosis of chronic obstructive pulmonary
disease, diabetes, or heart failure; and total number of
comorbidities (ordinal, nine levels). Trial related covariates
included WSD site, number of peripheral telehealth devices
installed (ordinal, five levels), and duration of exposure to
telehealth (in days) at short term and long term assessment
(continuous data). For all parameter tests, the α level was set
to 0.05.
We did intention to treat analyses to assess treatment
effectiveness, as the most appropriate strategy for analysing
pragmatic randomised controlled trials. However, this approach
is conservative and risks underestimating treatment effects.79 80
Complex healthcare interventions administered as part of a
pragmatic trial risk being administered suboptimally, compared
with being administered in routine care.
Obtaining an estimate of treatment efficacy would require a
heavily resourced explanatory randomised controlled trial.
However, an approximate evaluation of efficacy in pragmatic
randomised controlled trials can be achieved via per protocol
analyses. Thus, we conducted secondary per protocol analyses
that analysed patients according to the treatment received rather
than the treatment allocated (web appendix 3). Per protocol
analyses risk overestimating the potential benefits that would
be observed in routine practice. Considering primary (intention
to treat) and secondary (per protocol) analyses together can help
to disentangle treatments effects from implementation effects.
Sensitivity analyses assessed the robustness of the findings to
decisions taken at the analysis stage. Primary and secondary
analyses were conducted for complete and available case
cohorts. Here, data in the results section are taken from the
primary analyses unless specified as being from secondary
analyses.
Results
Descriptive statistics
At baseline, 1573 participants provided data in the questionnaire
study (845 allocated telehealth, 728 usual care). The overall
response rate was 62.7% (986/1573) at four months and 61.9%
(974/1573) at 12 months, with a higher rate for telehealth at
both assessments. Overall, 48.3% (759/1573) of questionnaire
participants were included in the complete case cohort, and
76.4% (1201/1573) in the available case cohort; again, with
higher rates for telehealth (fig 1). Participants receiving
telehealth in theWSD telehealth trial were thus more likely than
those receiving usual care to opt in to the questionnaire study,
more likely to provide data at both follow-up assessments, and
consequently more likely to be included in complete and
available case cohorts.
Table 1 presents sample characteristics for the 3230 participants
in the parent trial, the 1573 participants in the nested
questionnaire study at baseline, and those retained in the
available case (n=1201) and complete case (n=759) cohorts.
Compared to the parent trial, the complete case cohort in the
questionnaire study had proportionally more participants from
Kent, fewer non-white participants, fewer cases of chronic
obstructive pulmonary disease, more cases of heart failure, a
lower level of deprivation, and a higher level of education.
The trial arms were closely balanced in sample size in the parent
trial cohort (telehealth=49.7% (1605/3230), usual care=50.3%
(1625/3230)) but showed a marked discrepancy in the
questionnaire study’s complete case cohort (telehealth=56.8%
(431/759), usual care=43.2% (328/759)). This discrepancy
reflected the differences in response rates already described.
Relative to the parent trial cohort, the questionnaire study’s
complete case cohort also had differences between trial arms
in the proportion of participants in Cornwall and Newham, the
proportion of participants with each long term condition, and
the level of deprivation. The observed differences do not always
show predictable patterns when comparing the parent trial cohort
with the questionnaire study’s baseline, available case, and
complete case cohorts. Overall, table 1 shows that the
composition of the questionnaire study samples were subject
to potential bias—both in terms of patients who agreed to take
part in the questionnaire study (baseline) and those who
completed follow-up assessments—which underlines the need
for case mix adjustment in the analyses.
Preliminary unadjusted analyses
Figures 4⇓ and 5⇓ present unadjusted means and 95%
confidence intervals for all outcomes by trial arm at all time
points for the two analysis cohorts. The overlapping confidence
intervals suggest that differences between arms at each
assessment point were non-significant. Web tables 1 and 2
present similar analyses of unadjusted mean change scores.
Some significant differences suggested that the telehealth arm
had a slower rate of deterioration over time than the usual care
arm in physical component score, anxiety, and depressive
symptoms. However, the magnitude of all mean differences in
change scores failed to reach the trial definedMCID (web tables
1 and 2).
Primary analyses: treatment effectiveness
In intention to treat analyses, we used multilevel modelling to
control for the baseline score of the respective outcome
measures, key covariates, and the intracluster correlation (see
methods). Key covariates included age; sex; ethnicity; education;
deprivation; diagnoses of chronic obstructive pulmonary disease,
diabetes, and heart failure; number of comorbidities;WSD site;
number of peripheral telehealth devices installed; and duration
of exposure to telehealth at each assessment. Parameter
estimates, analogous to regression coefficients, and significance
level are shown for the main effects of trial arm (telehealth v
usual care) and time (short term v long term assessment) and
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their interaction for each of the outcome measures (table 2⇓).
Tests of the effects of the covariates are not presented. Table 2
shows that trial arm, time, and their interaction were not
significant for any outcome measure in either cohort.
To assist with the interpretation of table 2, web table 3 presents
unadjusted means at baseline and estimated marginal means
(EMMs) at short term and long term for all outcomes. EMMs
were derived from a model that accounted for the intracluster
correlation, all continuous or ordinal covariates, and baseline
outcome measure; but not categorical covariates (known as
“factors” within SPSS). For both cohorts, the pattern of means
and EMMs closely mirror the parameter estimates in table 2
and reaffirm that differences between trial arms are clinically
insubstantial. Minor differences of interpretation for some
outcomes between table 2 and web table 3 are explained by the
underlying differences in the statistical models used to generate
the values reported.
Figures 6⇓ and 7⇓ show the adjusted effect sizes for trial arm
(telehealth v usual care). Outcomes for both cohorts at short
term and long term failed to reach the trial defined MCID.
Further, all confidence intervals crossed zero, suggesting that
estimates of the true treatment effect in the population could
favour either telehealth or usual care. The true direction of the
effect is uncertain and the magnitude of the effect is clinically
insignificant.
Secondary analyses: treatment efficacy
In per protocol analyses, multilevel modelling generated no
significant main effects for trial arm or time for any outcome
measure in either cohort (table 3⇓). The two significant
interaction terms for the SF-12 mental component score and
CESD-10 in the complete case cohort reflect deteriorations for
telehealth at short term, whereas scores remained stable over
time for usual care (web table 4). The interaction findings were
not replicated in the available case cohort (table 3). Differences
between trial arms were unlikely to be clinically significant
(figs 8⇓ and 9⇓).
No adverse events or side effects related to any of the telehealth
devices were reported in the intervention group throughout the
trial.
Discussion
This large cluster randomised trial of second generation, home
based telehealth for patients with chronic obstructive pulmonary
disease, diabetes, or heart failure found no main effect of
telehealth on generic health related QoL, anxiety, or depressive
symptoms over 12 months. These null findings were consistent
across a series of sensitivity analyses for the five validated
outcome measures (tables 2 and 3). The null findings for the
primary intention to treat analyses show that telehealth is not
effective, while the null findings for the secondary per protocol
analyses show that telehealth is not efficacious. Assessed against
the trial defined MCID (equal to Cohen’s d=0.3), population
estimates showed that the small, non-significant differences
between trial arms in the primary analyses did not reach
clinically significant levels for any outcome, in any cohort, at
any time point (figs 6 and 7).
Exploratory investigations of trial arm×time interactions showed
two significant effects for the mental component of health
related QoL and depressive symptoms (table 3). At face value,
these findings suggest that telehealth participants deteriorated
at short term assessment before recovering to levels closer to
baseline (and closer to usual care scores) at long term. However,
these findings were not robust across sensitivity analyses, and
point estimates of effect size for these outcomes did not reach
clinical significance at either assessment point (figs 8 and 9;
table 3).
The overall consistency of results demonstrates that the findings
are robust to variations in attrition (complete case v available
case analyses), protocol fidelity (intention to treat v per protocol
analyses), and choice of outcome measure. The similarity of
the patient reported outcomes across trial arms suggests that
concerns about the potentially deleterious effect of telehealth8 50
are unfounded for most patients, since deterioration on any of
the five outcome measures over the assessment period was not
significant, compared with usual care. For the purposes of
service planning, the current findings should be considered with
other evidence from the WSD Evaluation on the effect of
telehealth on hospital use andmortality81 and cost effectiveness.82
Comparison with other studies
When comparing our findings to existing research, it is important
to distinguish between the statistical results reported in the extant
literature and the conclusions drawn by authors. When
considering only studies evaluating broadly equivalent forms
of telehealth (that is, home based, vital signs monitoring using
store and forward technology), systematic reviews have shown
that fewer than half found any significant benefits to health
related QoL,34 36 42 44 and those that did only found effects on
only a minority of the QoL measures used.49
Despite methodological variation across studies, these findings
suggest that the effect of telehealth on health related QoL is
weak or non-existent. To this extent, the available literature
concurs with the current findings. However, some authors have
observed that the conclusions drawn in many telehealth studies
are often unduly positive.42 53 With some notable exceptions,42
the current study’s conclusions therefore differ markedly from
most extant studies and reviews examining the effect on
telehealth on health related QoL, which are typically interpreted
as showing benefits despite presenting equivocal evidence.
The scope for inappropriate inferences is increased when small
andmethodologically weak studies generate inconclusive results.
The current findings underline the importance of using data
from adequately powered, high quality trials to make decisions
about telehealth implementation and caution against reliance
on meta-analyses based on small, poor quality studies.40 55 Our
findings for second generation telehealth over 12 months mirror
the recent null finding for third generation telehealth over 24
months.41 Few studies have examined the effect of telehealth
on anxiety or depressive symptoms, and the current findings
extend our understanding of these outcomes.
Strengths and limitations
TheWSD telehealth trial is one of the largest randomised studies
to evaluate the effect of telehealth on patient reported outcomes.
A total of 1573 participants from 154 general practices across
four primary care trusts (regional health authorities) provided
questionnaire data at baseline. For the intention to treat analysis,
1201 participants from 150 practices were included in the
available case cohort, and 759 from 131 practices in the
complete case cohort (fig 1). By including participants with any
of three long term conditions (chronic obstructive pulmonary
disease, diabetes, or heart failure), imposing minimal exclusion
criteria, and assessing participants over 12 months, the
generalisability of the findings is maximised. The inclusion of
three assessment points, multiple outcomemeasures, and robust
statistical methods affords greater confidence in the findings.
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Notwithstanding these strengths, some potential caveats should
be acknowledged. All practices in the four primary care trusts
were invited to participate in the WSD Evaluation, and 61%
(224/365) agreed and identified at least one patient whomet the
eligibility criteria and participated in either the WSD telehealth
trial (179 practices) or WSD telecare trial (217 practices). Data
for pretrial practice characteristics show that participating
practices differed in practice size, deprivation, ethnic
composition, diabetes prevalence, and WSD site, but had no
differences in the prevalence of chronic obstructive pulmonary
disease or heart failure (web appendix 4). Despite these
differences, recruited practices were not highly selected and
heterogeneity was preserved (web appendix 4). For example,
the percentages of non-participating practices categorised as
having a low, medium, or high proportion of non-white patients
were 32%, 43%, and 25% respectively, while corresponding
percentages for participating practices were 25%, 34%, and
41%, respectively.
Similar concerns could be raised about the representativeness
of participants in the questionnaire study. For practical and
ethical reasons, we were unable to collect data on all patients
who refused to participate in the WSD Evaluation at each stage
of recruitment. Nevertheless, table 1 shows selection bias in
those patients who agreed to participate in the nested
questionnaire study relative to the parent trial, and attrition bias
in those who were retained at follow-up. Participants allocated
to telehealth (in the parent trial) were more likely than those
allocated to usual care to agree to participate in the questionnaire
study and to complete one or both assessments. Reasons for the
relative advantage of the telehealth arm in recruitment and
retention are unclear, though it is consistent with the principle
of reciprocity; people receiving a notional benefit (such as
telehealth) are more likely to comply with subsequent requests.83
Potential threats to external validity from self selection or
attrition bias underline the need to take care when generalising
the results beyond the context of the trial. However, the
relatively high level of practice participation and the large and
heterogeneous participant sample support our assertion that any
effect on the external validity of the trial is likely to be minor.
Participants allocated to telehealth did not receive equivalent
treatments in all sites. Provision of peripheral telehealth devices
(web figure 1) and response to biometric readings (web appendix
2) varied substantially by site and long term condition, as did
the likelihood of having equipment removed prematurely for
reasons other than death (web figure 2). In a pragmatic trial,
this heterogeneity reflects the variability of implementation that
would be observed in a wider rollout of telehealth, thereby
increasing the generalisability of the findings.
In line with the original trial protocol, the analysis sought to
draw conclusions about a general class of technology (telehealth)
rather than about the effect of specific peripheral devices (pulse
oximeter, glucometer, weight scales, blood pressure monitor)
for specific long term conditions. Pooling patients with different
profiles of long term conditions could mask differential
treatment effects; therefore, planned analyses will examine the
effect of telehealth on health related QoL, anxiety, and
depressive symptoms for three subgroups of participants indexed
to one long term condition (chronic obstructive pulmonary
disease, diabetes, or heart failure).
We measured health related QoL using three generic scales
(SF-12 physical component score, SF-12 mental component
score, and EQ-5D) to assess different dimensions of the
construct. It is recommended that assessment of health related
QoL includes both generic and disease specific measures to
capture the full range of effect of illness on health related
QoL,84 85 and some evidence indicates that disease specific
measures are more sensitive to clinical change.86 Forthcoming
analyses will examine the effect of telehealth on these disease
specific measures. Although patient reported outcomes were
the a priori primary endpoint, disease specific clinical markers
would have afforded a more comprehensive description of the
sample. Such markers include forced expiratory volume ratio
for chronic obstructive pulmonary disease, HbA1c for diabetes,
and the New York Heart Association classification for heart
failure. Unfortunately, there were logistical barriers to the timely
acquisition of clinical biomarkers. The planned analyses of
disease specific measures of health related QoL (that is the
chronic respiratory questionnaire, diabetes health profile, and
Minnesota Living with Heart Failure questionnaire) will go
some way to describing the clinical severity of the long term
condition samples.
Despite providing an extensive description of the implemented
telehealth treatment across sites and conditions (web appendix
2; fig 1, web fig 1), there were inevitably some aspects of the
treatment where detailed data were unavailable. We do not have
detailed information about changes to treatment or other clinical
decisions initiated in response to telehealth data. Detailed
information was not available about the degree to which
telehealth participants adhered to their behavioural regimens
(such as monitoring schedules, treatment adherence). We also
do not have detailed information on the degree to which the
telehealth technology encountered technical problems that
interfered with measurement or the exchange of messages
between participants and the monitoring centres. However,
although about 20% of telehealth participants in the
questionnaire study had their equipment removed prematurely
during the trial (web fig 2), 80% retained telehealth services for
the full 12 months; alternatively, around 10% of telehealth
participants had their equipment removed in the first six months
of the trial while 90% retained it for longer. In web appendix
2, protocols used by the monitoring centres show that any
missing measurement sessions (whether from technical failure
or participant non-adherence) were responded to within 72 h.
Therefore, equipment failure or non-adherence are not plausible
explanations for the observed null findings.
A further issue concerns the particular version of telehealth
evaluated in the parent trial. Telehealth was implemented as
monitoring of vital signs done daily (up to five days per week),
supplemented by questions assessing health status and symptom
severity, plus an educational component. The educational
component consisted of brief textual information delivered
through a static telehealth base unit with a small liquid crystal
display (LCD) screen (Cornwall and Kent) or a dedicated
interactive television channel (Newham). Telehealth participants
in Newham could also watch short educational videos with
disease specific information. Physiological and symptom report
data were transferred to a monitoring centre using store and
forward technology. In terms of a recently proposed
classification of telehealth,40 the telehealth system evaluated
here most closely approximates a second generation system.
The current findings therefore cannot be generalised to third or
fourth generation systems that involve both invasive and
non-invasive physiological monitoring with real time analytical
and decision making support by physicians or physician led
specialist nurses. Telehealth can only be studied as technology
in use, and research evidence will always lag behind the latest
technological advances.87 However, most systems that have
been tested so far represent first or second generations; third or
fourth generations should be recognised a distinct class of
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intensive interventions for select clinical populations at high
risk.
The parent trial was set in the context of Whole Systems
Redesign, and the three WSD sites were selected on the basis
of having achieved substantial integration of health and social
care. Assuming that this integration improves outcomes, the
trial sought to identify any added benefit of telehealth services
beyond those accrued from enhanced integration. In contexts
with less integrated health and social care, telehealth benefits
may be more likely to emerge. This argument assumes that
integrated health and social care generates ceiling or floor effects
for health related QoL, anxiety, and depressive symptoms.
However, the baseline means show that our sample had similar
health related QoL to other comparable clinical samples88 with
scope for either improvement or deterioration (figs 4 and 5). It
is therefore unlikely that the lack of observed telehealth benefits
can be attributed to the integrated care context or to recruitment
of atypical clinical samples.
Shouldwe expect telehealth to improve health
related QoL or psychological outcomes?
If telehealth delivers tailored healthcare that is acceptable to
patients and facilitates more responsive interventions from
professionals, resulting in better disease control with fewer
exacerbations and admissions, we might expect corresponding
improvements in health relatedQoL and psychological outcomes
over time. Similarly, if telehealth leads to improved self care
behaviour and efficacy, we might expect increases in health
related QoL and reductions in negative affect. It remains unclear
whether improvements in these patient reported outcomes are
driven primarily by objective improvements in physical health,
or by subjective improvements in perceptions of agency or
control. Alternatively, telehealth could reduce health related
QoL and psychological wellbeing owing to the increased burden
of self monitoring, concerns about intrusive surveillance, a
perceived lack of user friendliness, or the undermining of the
traditional (face-to-face) therapeutic relationship. More research
is required to understand the many potential beneficial and
harmful mechanisms by which telehealth could affect patient
reported outcomes. However, our findings strongly suggest no
net benefit from telehealth; therefore, it should not be used as
a tool to improve health related QoL or psychological outcomes.
Future directions
The current findings point to other avenues of enquiry. Planned
subgroup analyses for chronic obstructive pulmonary disease,
diabetes, and heart failure using disease specific outcomes of
health related QoL represent the next step in this process.
Alternative measures of health gain (such as self care, perceived
impact of illness, and activities of daily living) are available for
participants in theWSD telehealth questionnaire study and may
offer a different perspective on the potential effect of telehealth.
Effects of telehealth might not be uniform across all patients,
and analyses may suggest subgroups of patients for whom
telehealth is either particularly beneficial or harmful.
Building on existing qualitative work from the WSD
Evaluation89 and the data in web figure 2, we aim to identify
predictors of early removal of telehealth. Quantitative analyses
will also explore intervention participants’ and carers’
perceptions of telehealth over the course of the study, and ask
whether these perceptions moderate outcomes. Other research
questions in the WSD Evaluation are identified in the protocol
paper.18
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Tables
Table 1| Sample characteristics at baseline. Data are no (%) unless stated otherwise
WSD telehealth questionnaire study (nested study)WSD telehealth trial (parent
trial) Complete case cohortAvailable case cohortBaseline cohort
Total
(n=759)
UC
(n=328;
43.2%)
TH
(n=431;
56.8%)
Total
(n=1201)
UC
(n=531;
44.2%)
TH
(n=670;
55.8%)
Total
(n=1573)
UC
(n=728;
46.3%)
TH
(n=845;
53.7%)
Total
(n=3230)
UC
(n=1625;
50.3%)
TH
(n=1605;
49.7%)
WSD site
256
(33.7)
107
(32.6)
149
(34.6)
389
(32.4)
168
(31.6)
221
(33.0)
490
(31.2)
234
(32.1)
256
(30.3)
1191
(36.9)
625
(38.5)
566
(35.3)
Cornwall
355
(46.8)
153
(46.6)
202
(46.9)
501
(41.7)
216
(40.7)
285
(42.5)
626
(39.8)
283
(38.9)
343
(40.6)
1178
(36.5)
595
(36.6)
583
(36.3)
Kent
148
(19.5)
68 (20.7)80 (18.6)311
(25.9)
147
(27.7)
164
(24.5)
457
(29.1)
211
(29.0)
246
(29.1)
861
(26.7)
405
(24.9)
456
(28.4)
Newham
Sex
295
(38.9)
124
(37.8)
171
(39.7)
478
(39.8)
207
(39.0)
271
(40.4)
640
(40.7)
290
(39.8)
350
(41.4)
1322
(40.9)
658
(40.5)
664
(41.4)
Female
464
(61.1)
204
(62.2)
260
(60.3)
723
(60.2)
324
(61.0)
399
(59.6)
933
(59.3)
438
(60.2)
495
(58.6)
1908
(59.1)
967
(59.5)
941
(58.6)
Male
Ethnicity*
53 (7.0)23 (7.0)30 (7.0)143
(11.9)
68 (12.8)75 (11.2)211.4
(13.4)*
99.9
(13.7)*
111.5
(13.2)*
367
(11.4)†
180
(11.1)†
187
(11.7)†
Non-white
706
(93.0)
305
(93.0)
401
(93.0)
1058
(88.1)
463
(87.2)
595
(88.8)
1361.6
(86.6)*
628.1
(86.3)*
733.5
(86.8)*
2515
(77.9)†
1264
(77.8)†
1251
(77.9)†
White
—————————348
(10.8)†
181
(11.1)†
167
(10.4)†
Data missing
Long term condition diagnoses‡
396
(52.2)
158
(48.2)
238
(55.2)
576
(48.0)
237
(44.6)
339
(50.6)
743
(47.2)
327
(44.9)
416
(49.2)
1864
(57.7)
962
(59.2)
902
(56.2)
COPD
236
(31.1)
108
(32.9)
128
(29.7)
448
(37.3)
205
(38.6)
243
(36.3)
622
(39.5)
283
(38.9)
339
(40.1)
1055
(32.7)
485
(29.8)
570
(35.5)
Diabetes
340
(44.8)
162
(49.4)
178
(41.3)
532
(44.3)
248
(46.7)
284
(42.4)
663
(42.1)
327
(44.9)
336
(39.8)
1147
(35.5)
581
(35.8)
566
(35.3)
Heart failure
Other (mean (SD))
70.87
(10.29)
71.21
(11.00)
70.61
(9.72)
70.28
(11.26)
70.46
(11.61)
70.14
(10.98)
70.34
(11.79)
70.61
(11.78)
70.11
(11.81)
70.24
(11.61)
70.80
(11.64)
69.68
(11.55)
Age (years)
25.01
(13.35)*
25.76
(12.96)*
24.44
(13.62)*
27.01
(14.07)*
28.10
(13.77)*
26.15
(14.24)*
28.10
(14.46)*
28.55
(13.79)*
27.71
(15.01)*
28.13
(14.18)†
27.93
(13.53)†
28.34
(14.82)†
Deprivation
(IMD)*
1.81
(1.80)
1.93
(1.84)
1.72
(1.76)
1.92
(1.83)
2.00
(1.88)
1.85
(1.78)
1.92
(1.83)
2.02
(1.86)
1.84
(1.80)
1.77
(1.81)
1.80
(1.82)
1.75
(1.79)
No of
comorbidities
1.54
(1.42)
0.04
(0.32)
2.69
(0.65)
1.56
(1.46)
0.07
(0.47)
2.74
(0.69)
1.52
(1.47)
0.07
(0.49)
2.77
(0.68)
1.35
(1.43)
0.04
(0.36)
2.68
(0.70)
No of TH
devices
TH=telehealth; UC=usual care; COPD=chronic obstructive pulmonary disease; IMD=index of multiple deprivation score; available case cohort=includes baseline
assessments and short term or long term assessment; complete case cohort=includes assessments at all three time points (baseline, four months (short term),
12 months (long term)).
*Participants (≤12) had missing data for ethnicity or deprivation in some cohorts of the questionnaire study. Missing values were multiply imputed (m=10), and the
values reported are imputed averages.
†The parent trial cohort had more participants than the questionnaire study cohort with missing data for ethnicity (n=348) and deprivation (n=12). These missing
values were not imputed; instead, missing values are reported explicitly for ethnicity, while for deprivation we reported the means (and standard deviations) based
on 3218 (99.6%) participants with data available. All other values are based on complete (non-imputed) data.
‡Participants could have had more than one diagnosis; therefore, the percentages do not add up to 100%.
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Table 2| Parameter estimates for trial arm, time, and their interaction, intention to treat analysis
Available case cohort (n=1201)Complete case cohort (n=759)
Outcome
Measure
Time×trial armTime†Trial arm*Time×trial armTime†Trial arm*
P
Estimate
(SE)P
Estimate
(SE)P
Estimate
(SE)P
Estimate
(SE)P
Estimate
(SE)P
Estimate
(SE)
0.923−0.13
(1.36)
0.843+0.08
(0.38)
0.181+2.32
(1.73)
0.795+0.38
(1.47)
0.771+0.12
(0.40)
0.480+1.59
(2.26)
PCS scale
(US 1998
NBS)
0.557−1.02
(1.73)
0.147−0.70
(0.49)
0.440−1.74
(2.25)
0.200−2.37
(1.85)
0.097−0.83
(0.50)
0.597−1.55
(2.93)
MCS scale
(US 1998
NBS)
0.820−0.01
(0.05)
0.570+0.01
(0.01)
0.383+0.05
(0.06)
0.807+0.01
(0.05)
0.360+0.01
(0.01)
0.904−0.01
(0.07)
EQ-5D
scale
0.897+0.09
(0.67)
0.791+0.05
(0.18)
0.905+0.10
(0.84)
0.765+0.21
(0.72)
0.953−0.01
(0.19)
0.866+0.18
(1.07)
Brief STAI
scale
0.262+0.99
(0.88)
0.974-0.01
(0.24)
0.293−1.20
(1.14)
0.157+1.34
(0.95)
0.865+0.04
(0.25)
0.812−0.35
(1.46)
CESD-10
scale
PCS=physical component score; MCS=mental component score; NBS=norms based scoring; SE=standard error.
Data are based on multilevel models controlling for the intraclass correlation, all covariates, and the relevant baseline outcome measure. Parameter estimates
can be interpreted as the observed difference in an outcome measure (for example, PCS) between levels of a predictor variable (for example, telehealth v usual
care) when the intracluster correlation and all covariates are taken into account. For example, parameter estimate +1.59 for trial arm on the PCS scale indicates
that patients receiving telehealth had a score 1.59 units higher than patients receiving usual care (reference category) when the intraclass correlation, all covariates,
and the baseline PCS score are taken into account.
*Telehealth=0; usual care=1 (reference category).
†Baseline assessment=1, short term assessment (at four months)=2, long term assessment (at 12 months)=3 (reference category). For the time variable, the main
effect tests the hypothesis that outcome measure differs between short and long term assessments while controlling for baseline scores and other covariates,
including trial arm (that is, testing the effect of time on the outcome measure, while the effect of trial arm and all other covariates held constant).
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Table 3| Parameter estimates for trial arm, time, and their interaction, per protocol analysis
Available case cohort (n=1108)Complete case cohort (n=633)
Outcome
measure
Time×trial armTime†Trial arm*Time×trial armTime†Trial arm*
P
Estimate
(SE)P
Estimate
(SE)P
Estimate
(SE)P
Estimate
(SE)P
Estimate
(SE)P
Estimate
(SE)
0.994−0.02
(2.96)
0.926−0.04
(0.40)
0.696+1.04
(2.66)
0.476+2.55
(3.58)
0.975+0.01
(0.43)
0.761−1.17
(3.82)
PCS (US
1998 NBS)
scale
0.058−7.07
(3.73)
0.217−0.63
(0.51)
0.179+4.54
(3.38)
0.013−10.88
(4.37)
0.105−0.87
(0.53)
0.724+1.74
(4.91)
MCS (US
1998 NBS)
scale
0.445+0.08
(0.10)
0.357+0.01
(0.01)
0.573−0.05
(0.09)
0.264+0.14
(0.12)
0.323+0.02
(0.02)
0.316−0.12
(0.12)
EQ-5D
scale
0.258+1.62
(1.43)
0.564−0.11
(0.19)
0.315−1.29
(1.28)
0.129+3.10
(1.70)
0.463−0.15
(0.21)
0.273−1.93
(1.76)
Brief STAI
scale
0.062+3.65
(1.96)
0.636−0.12
(0.26)
0.145−2.53
(1.73)
0.007+6.41
(2.37)
0.945−0.02
(0.27)
0.294−2.63
(2.51)
CESD-10
scale
PCS=physical component score; MCS=mental component score; NBS=norms based scoring; SE=standard error.
Data are based on multilevel models controlling for baseline outcome score, all covariates and intraclass correlation. No specific hypotheses were made about
the effect of telehealth on particular outcomes at particular time points; therefore, any investigation of time×trial arm interaction terms must be considered exploratory
(hypothesis generating) rather than confirmatory (hypothesis testing). The value afforded to such findings when drawing inferences must be weighted accordingly.
Moreover, sensitivity analyses across multiple outcomes, cohorts, analytical approaches (intention to treat v per protocol), and parameters (trial arm, time, trial
arm×time) leads to the reporting of 60 significance tests (tables 2 and 3). At the stated α level of 0.05, we would expect three of these to be significant by chance
alone, while reducing α to 0.01 would render one of the two significant interaction term in table 3 (complete case cohort) non-significant. The lack of significant
interaction terms in the primary analyses (for both cohorts) and secondary analyses (available case cohort) highlights the general lack of robustness. Furthermore,
trial arm×time interaction terms were not significant for PCS, EQ-5D, or CESD-10 in table 3 despite ostensibly measuring closely related constructs. When a trial
produces overwhelmingly null results, there is a danger of overemphasising any significant findings, but consideration of the salient factors shows that the two
significant interaction terms are not robust, with reasonable likelihood that they reflect chance effects resulting from the additional inclusion criteria applied in the
secondary analyses. They should be interpreted with caution.
*Telehealth=0; usual care=1 (reference category).
†Short term assessment (at four months)=2, long term assessment (at 12 months)=3 (reference category). The only a priori hypothesis made about telehealth
was that it would improve health related QoL and psychological outcomes relative to usual care.
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Figures
Fig 1 CONSORT diagram of the WSD telehealth trial and WSD telehealth questionnaire study. *Recruitment into the
questionnaire study was implemented at the patient level, but descriptive data at the cluster level (general practice) are
presented for comparison with the parent trial. †Allocated treatment based on the installation of any telehealth device (pulse
oximeter, glucometer, weighing scales, or blood pressure monitor) regardless of participant’s diagnosed condition. ‡Allocated
treatment based on the installation of at least one “critical” telehealth device for a diagnosed condition (web appendix 2).
§Second set of brackets show number of active practices, and median number and range of participants per practice
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Fig 2 Composition of baseline sample, by diagnosis of long term condition. COPD=chronic obstructive pulmonary disease
Fig 3 Overview of WSD telehealth intervention. Numbers indicate stages described in web appendix 2
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Fig 4 Outcomes for complete case cohort (n=759). Short term assessment at four months, long term assessment at 12
months
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Fig 5 Outcomes for available case cohort (n=1201). Short term assessment at four months, long term assessment at 12
months
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Fig 6 Standardised adjusted effect sizes for intention to treat analysis, complete case cohort. Effect sizes (mean differences)
were calculated at short term and long term, on the basis of EMMs. Web table 3 shows numbers for each arm at each
assessment point. Unstandardised mean differences represent the estimated (adjusted) magnitude of difference between
arms in the original scale metric. Standardised mean differences allow for direct comparisons across different outcomes.
These standardardised mean differences were calculated with a correction for sample size (Hedge’s g), and are interpreted
in the same way as Cohen’s d
Fig 7 Standardised adjusted effect sizes for intention to treat analysis, available case cohort. Web table 3 shows numbers
for each arm at each assessment point
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Fig 8 Standardised adjusted effect sizes for per protocol analysis, complete case cohort. Web table 4 shows numbers for
each arm at each assessment point
Fig 9 Standardised adjusted effect sizes for per protocol analysis, available case cohort. Web table 4 shows numbers for
each arm at each assessment point
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